Costs and Expenses of Y-mAbs Therapeutics, Inc. from 31 Dec 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Y-mAbs Therapeutics, Inc. quarterly and annual Costs and Expenses in USD history and change rate from 31 Dec 2019 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Costs and Expenses for the quarter ending 30 Jun 2025 was $22,467,000, a 24% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. Costs and Expenses for the twelve months ending 30 Jun 2025 was $96,483,000, a 1.3% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Costs and Expenses for 2024 was $103,885,000, a 4.8% increase from 2023.
  • Y-mAbs Therapeutics, Inc. annual Costs and Expenses for 2023 was $99,125,000, a 38% decline from 2022.
  • Y-mAbs Therapeutics, Inc. annual Costs and Expenses for 2022 was $160,078,000, a 6.5% increase from 2021.
Source SEC data
View on sec.gov
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Change (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $96,483,000 $22,467,000 -$7,106,000 -24% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $103,589,000 $24,446,000 -$296,000 -1.2% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $103,885,000 $22,541,000 +$7,345,000 +48% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $96,540,000 $27,029,000 -$1,174,000 -4.2% 01 Jul 2024 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $97,714,000 $29,573,000 +$1,599,000 +5.7% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $96,115,000 $24,742,000 -$3,010,000 -11% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $99,125,000 $15,196,000 -$17,405,000 -53% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $116,530,000 $28,203,000 -$10,351,000 -27% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $126,881,000 $27,974,000 -$22,768,000 -45% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $149,649,000 $27,752,000 -$10,429,000 -27% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $160,078,000 $32,601,000 -$12,755,000 -28% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $172,833,000 $38,554,000 +$885,000 +2.3% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $171,948,000 $50,742,000 +$17,079,000 +51% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $154,869,000 $38,181,000 +$4,539,000 +13% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $150,330,000 $45,356,000 +$4,511,000 +11% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $145,819,000 $37,669,000 +$5,028,000 +15% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $140,791,000 $33,663,000 -$6,789,000 -17% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2021 Q3
Q1 2021 $147,580,000 $33,642,000 +$6,895,000 +26% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $140,685,000 $40,845,000 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $32,641,000 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $40,452,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $26,747,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1

Y-mAbs Therapeutics, Inc. Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $103,885,000 +$4,760,000 +4.8% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $99,125,000 -$60,953,000 -38% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $160,078,000 +$9,748,000 +6.5% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $150,330,000 +$9,645,000 +6.9% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $140,685,000 +$57,681,000 +69% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $83,004,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.